Clinical Trial Update: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma [Phase 2]

View source ↗

Summary

A Phase II, two-arm trial evaluating everolimus and letrozole with or without ribociclib (Lee011) in patients with advanced or recurrent endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Carcinoma
• Endometrioid Endometrial Adenocarcinoma

Drugs mentioned

• Afinitor (everolimus)
• FEMARA (letrozole)
• KISQALI (ribociclib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING